STRL is down -8.26% during regular trading, near $378.83 versus its $412.96 prior close. The decline extends a sector-wide sell-off in construction and infrastructure names, driven by renewed fears that E-Infrastructure segment margins could shrink.
ITG, Inc. (Nasdaq: ITG) fell -8.51% to $4.73 in regular trading on Oct. 22, 2026, from the prior close of $5.17. The primary catalyst was Stifel cutting its price target to $9 from $16 while keeping a Buy rating, citing soft wireless/cable-coax demand and higher fuel costs as Q3 headwinds.
MTZ is trading down -4.26% (-$7.98) to $179.36 during the regular session, extending a 10-session losing streak that has already erased roughly -18% of its value. The slide reflects an ongoing reversal in the AI/power-infrastructure trade, as investors question the pace and financing of data-center and power build-out spending.
Cardinal Infrastructure Group (CDNL) fell roughly 54.6% over the trailing 30 days, declining from about $31.52 on September 21, 2026 to $14.32 by late October 2026. The drop extends a broader multi-month selloff, with shares down about 80.6% from their late-July level of roughly $73.96.
Dycom Industries (DY) shares have declined roughly 17.8% over the last 30 days, falling from a close near $291.55 to a recent level around $239.73. The slide extends a deeper quarterly decline of about 43%, as investors continue to digest margin pressure and deferred wireless revenue disclosed with fiscal Q2 2027 results.
DY fell -4.86% to about $239.75 during regular trading, extending a steep multi-week selloff toward 52-week lows. The drop follows fiscal Q2 2027 results, where record revenue was overshadowed by weak Q3 EPS guidance ($4.33–$4.79 vs. $4.79 consensus) and roughly $150M in wireless revenue deferred into FY2028.
CDNL is trading down -5.13% intraday during regular market hours, falling to $14.42 from a prior-session close of $15.20. The decline extends a sharp multi-day selloff that has dragged the stock toward its 52-week low near $14.
FIX fell about -4.10% during today's regular session to roughly $1,404, after gapping down over 5% at the open from a $1,464.07 prior close. Primary catalyst: Goldman Sachs cut its price target to $1,875 from $2,159 (kept Buy), citing falling engineering & construction valuations and doubts about hyperscaler data-center capex durability and post-2027 earnings power.
LGN traded down -4.43% to about $42.25 during regular market hours, from a prior close of $44.21. The primary catalyst was a Zacks Research downgrade to Hold from Strong Buy, sending shares as low as roughly $41.
CDNL is trading down -6.74% at $14.80 during regular market hours Tuesday, giving back the prior session's +8.55% gain from $15.87. The decline deepens a multi-week slide that has the stock near its 52-week low of $14.09, down roughly 80% from its $96.40 high.
FBGL (FBS Global Limited) is a Singapore-based green building contractor with a micro-cap valuation of roughly $5 million, while VSTM (Verastem, Inc.) is an oncology-focused biopharmaceutical company valued near $675 million. The two names sit in entirely different sectors and risk profiles, making this a study in contrasting market positioning rather than a like-for-like peer comparison.
Different industries, similar micro-cap profile: FBGL operates as a Singapore-based green building contractor, while NXGL is a U.S. healthcare and medical technology company focused on hydrogel products. Both companies are unprofitable on a trailing twelve-month (TTM) basis, with negative earnings per share (EPS) and limited institutional ownership.
Both FBGL and FMFC are micro-cap companies listed on the Nasdaq Capital Market, and both recently used share consolidations to address minimum-bid-price listing requirements. FBGL (FBS Global Limited) operates as a Singapore-based green building contractor and interior fit-out specialist, while FMFC (Kandal M Venture Limited) manufactures and sells handbags across the United States, Europe, Canada, and Japan.
BDRX is a clinical-stage biopharmaceutical company with no commercial revenue, while FBGL is a Singapore-based green building contractor with an established revenue base. Both stocks have recently completed share consolidations, but for different reasons: BDRX executed a 10,000-for-1 reorganization, while FBGL used a 1-for-10 reverse split to restore Nasdaq compliance.
CORD (Cordiant Digital Infrastructure) is a London-listed owner and operator of digital infrastructure assets with a market capitalization of roughly £926 million. FBGL (FBS Global) is a Nasdaq-listed green building contractor based in Singapore with a micro-cap valuation of only about $5 million.
FBGL is a Singapore-based green building contractor that listed on Nasdaq in early 2025, while NCPL is a Boston-based fintech operating a digital private capital markets platform. The two companies occupy entirely different industries — construction and engineering versus financial technology — making this a study in contrasting business models and risk profiles.
FBGL is a Singapore-based green building contractor and interior fit-out specialist, while LQDA is a U.S. biopharmaceutical company focused on respiratory and vascular diseases. The two companies operate in entirely different sectors, with sharply contrasting growth profiles, risk factors, and market capitalizations.
FBGL (FBS Global Limited) is a Singapore-based green building contractor and interior fit-out specialist with a very small market capitalization, contributing to elevated volatility in recent weeks. GENK (GEN Restaurant Group, Inc.) operates a growing Korean barbecue restaurant chain in the United States with a meaningfully larger revenue base than FBGL.
FBGL (FBS Global Limited) is a Singapore-based green building contractor with a sub-$5 million market capitalization, recently relying on a reverse stock split to maintain its Nasdaq listing. TCRT (Alaunos Therapeutics, Inc.) is a pre-clinical biopharmaceutical company pivoting toward obesity and metabolic disorder treatments, trading at a similarly micro-cap scale.
FBGL is a Singapore-based green building contractor that recently used a 1-for-10 share consolidation (reverse split) to restore Nasdaq minimum bid price compliance, while its shares have still declined sharply in 2026. GRML is a small-cap holding company spanning cell and gene therapy and natural resources, formerly known as Klotho Neurosciences before its March 2026 name change.